An FDA advisory panel recommended in late June that Avastin should no longer be used to treat breast cancer.
An FDA advisory panel recommended in late June that Avastin should not be used to treat breast cancer.
FDA’s Oncology Drug Panel voted unanimously that Avastin’s approval for breast cancer treatment be withdrawn. During the hearings, patient groups such as the Abigail Alliance fought for continued use of Avastin in breast cancer treatment.
Avastin was first approved in 2004 to treat advanced colon cancer and has since been approved for lung, kidney, and brain cancers. FDA proposed withdrawing Avastin’s approval to treat metastatic breast cancer in late 2010, saying that there was not enough evidence to show that the drug is safe and effective for breast cancer treatment.
Avastin’s manufacturer, Genentech, a subsidiary of Roche, lobbied FDA and Congress for a second hearing on the issue in late December. Avastin generates more than $6 billion a year for the company, according to news reports.
The advisory panel recommendation does not signify a final FDA decision. FDA’s public comment period on Avastin withdrawal remains open until July 28, 2011. Sometime after that, FDA Commissioner Margaret Hamburg will make a final decision on use of Avastin use for breast cancer.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.